|
|
|
| Insurance-based compensation for adverse reactions following vaccination in Jiaxing City |
| TANG Xian, DU Zhequn, YU Pengfei, SONG Yiping, SHEN Guochu, HU Jie
|
| Jiaxing Center for Disease Control and Prevention, Jiaxing, Zhejiang 314050, China |
|
|
|
|
Abstract Objective To analyze the insurance-based compensation provided by basic and supplementary insurance for adverse reactions following vaccination in Jiaxing City, Zhejiang Province, so as to provide a basis for improving the vaccine insurance compensation mechanism and promoting vaccination services. Methods Individual records of insurance compensation for adverse reactions following vaccination in Jiaxing City from 2024 to 2025 were collected. A descriptive analysis was conducted to characterize the number of insurance-based compensation cases, compensation amounts, severity grades, vaccine types and clinical diagnoses. Results A total of 479 cases of adverse reactions following vaccination received insurance-based compensation in Jiaxing City, with a total compensation amount of 1 538 900 yuan. Basic insurance compensated 9 cases, with a total compensation amount of 683 600 yuan. Among these, one case classified as Grade Ⅲ, Class B received compensation of 656 000 yuan, while eight cases classified as Grade Ⅳ and other cases received compensation totaling 27 600 yuan. Supplementary insurance compensated 470 cases, with a total compensation amount of 855 300 yuan. One death case involving a coincidental illness received compensation of 150 000 yuan, 469 Grade Ⅳ and other cases received compensation totaling 705 300 yuan. The three most frequently compensated vaccine categories under supplementary insurance were diphtheria and tetanus toxoid with acellular pertussis, inactivated poliovirus vaccine-inactivated, and Haemophilus influenzae type B vaccine (DTaP-IPV-Hib), combined vaccination with hepatitis B vaccine (HepB) and bacille calmette-guérin vaccine (BCG), and 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), accounting for 72, 54 and 39 cases, respectively. The three vaccine categories associated with the highest compensation amounts were combined vaccination with HepB and BCG, DTaP-IPV-Hib, and PCV13, with compensation amounts of 263 700, 125 300 and 48 300 yuan, respectively. The three most common clinical diagnoses among compensated cases were acute upper respiratory tract infection, pneumonia and acute bronchitis, accounting for 175, 81 and 54 cases, respectively. Conclusions The insurance-based compensation mechanism for adverse reactions following vaccination in Jiaxing City demonstrates a tiered coverage pattern: basic insurance primarily covers severe cases, while supplementary insurance mainly covers mild cases. Surveillance of adverse reactions following vaccination associated with standalone administration of DTaP-IPV-Hib, combined vaccination with HepB and BCG, and PCV13 should be strengthened, and particular attention should be paid to distinguishing coincidental illness.
|
|
Received: 02 July 2026
Revised: 01 September 2026
Published: 27 October 2026
|
|
|
|
|
|
[1] 全国人民代表大会常务委员会.中华人民共和国疫苗管理法[EB/OL].[2026-09-01].https://www.samr.gov.cn/zw/zfxxgk/fdzdgknr/fgs/art/2023. [2] 张彩霞,谭妙婵,温菊香.79例疑似预防接种异常反应疫苗纠纷案例分析——以司法裁判文书为视角[J].中国卫生法制,2020,28(1):27-34. [3] 中华人民共和国国家卫生健康委员会.国家卫生计生委办公厅关于印发国家免疫规划儿童免疫程序及说明(2016年版)的通知[EB/OL].[2026-09-01].https://www.nhc.gov.cn/jkj/c100063/201612/0f651acf2863404189dafde304337407.shtml. [4] 罗美玲,张英,刘浩,等.长沙市儿童家长购买预防接种异常反应补充保险的影响因素分析[J].预防医学,2020,32(8):774-777. [5] 浙江省疾病预防控制中心.浙江省疾病预防控制中心关于印发浙江省免疫规划疫苗预防接种异常反应补偿保险实施方案(试行)的通知[EB/OL].[2026-09-01].https://zjjcmspublic.oss-cn-hangzhou-zwynet-d01-a.internet.cloud.zj.gov.cn/jcms_files/jcms1/web3595/site/attach/0/53b172b217e54e18bffafe1f0369e09e.pdf. [6] 中华人民共和国中央人民政府.医疗事故分级标准(试行)[EB/OL].[2026-09-01].https://www.gov.cn/gongbao/content/2003/content_62085.htm. [7] 浙江省卫生健康委员会.浙江省预防接种异常反应补偿办法(试行)[EB/OL].[2026-09-01].https://zjyxjl.org.cn/news/detailn_id=192&wn=9&apply=0. [8] 黄鹏辉.预防接种异常反应的保险补偿机制研究[D].北京:首都经济贸易大学,2019:11,21,24-25. [9] 杨旭,王玲玲,王旭雯.2020—2022年江苏省无锡市预防接种异常反应保险补偿分析[J].上海预防医学,2024,36(8):814-822. [10] 臧秀娟,姜婷,王芳芳.2021—2023年宿迁市宿城区商业保险补偿在预防接种异常反应中的使用情况分析[J].中国校医,2025,39(3):235-240. [11] 许濒月,邓瑞楠,韩真明,等.2018—2021年重庆市预防接种异常反应保险补偿分析[J].中国疫苗和免疫,2022,28(4):451-457. [12] Pieren D K J,Boer M C,De Wit J.The adaptive immune system in early life:the shift makes it count[J/OL].Front Immunol,2022,13[2026-09-01].http://doi.org/10.3389/fimmu.2022.1031924. [13] 刘建华. 3例儿童预防接种偶合疾病性质分析[J].中国儿童保健杂志,2015,23(2):223-224. |
|
|
|